Send to:

Choose Destination
See comment in PubMed Commons below
Nat Med. 2007 May;13(5):552-9.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Author information

  • 1Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA.


The identification of the antigen recognition receptors for innate immunity, most notably the Toll-like receptors, has sparked great interest in therapeutic manipulation of the innate immune system. Toll-like receptor agonists are being developed for the treatment of cancer, allergies and viral infections, and as adjuvants for potent new vaccines to prevent or treat cancer and infectious diseases. As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk